Latest Period
Q4 2025
Security Snapshot
Design Therapeutics, Inc. - Common Stock, $0.0001 par value per share (DSGN) Institutional Ownership
CUSIP: 25056L103
13F Institutional Holders and Ownership History from Q1 2021 to Q1 2026
Institutions Reporting
116
Shares (Excl. Options)
38,119,020
Price
$9.38
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, $0.0001 par value per share
- Symbol
- DSGN on Nasdaq
- Shares outstanding
- 61,756,000
- Price per share
- $10.64
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 38,119,020
- Total reported value
- $357,552,417
- % of total 13F portfolios
- 0%
- Share change
- +3,292,284
- Value change
- +$35,421,791
- Number of holders
- 116
- Price from insider filings
- $10.64
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- DSGN - Design Therapeutics, Inc. - Common Stock, $0.0001 par value per share is tracked under CUSIP 25056L103.
- 116 institutions reported positions in Q4 2025.
- 5 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 116 to 54 between Q4 2025 and Q1 2026.
- Reported value moved from $357,552,417 to $68,711,725.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 116 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 25056L103?
CUSIP 25056L103 identifies DSGN - Design Therapeutics, Inc. - Common Stock, $0.0001 par value per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 25056L103:
Significant Owners of Design Therapeutics, Inc. - Common Stock, $0.0001 par value per share (DSGN) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| SR One Capital Fund I Aggregator LP | 11% | $62,048,106 | 6,607,892 | Simeon George | 09 Mar 2026 | |||
| Point72 Asset Management, L.P. | 9.4% | +84% | $50,443,118 | +$22,810,986 | 5,372,004 | +83% | Point72 Asset Management, L.P. | 31 Dec 2025 |
| Light Irrevocable Trust #1 dated April 22, 2019 | 6.9% | $16,257,665 | 3,834,355 | Light Irrevocable Trust #1 dated April 22, 2019 | 31 Dec 2024 | |||
| Star Irrevocable Trust #1 dated April 22, 2019 | 6.9% | $16,257,665 | 3,834,355 | Star Irrevocable Trust #1 dated April 22, 2019 | 31 Dec 2024 | |||
| Logos Global Management LP | 4.4% | -22% | $16,322,350 | -$4,802,600 | 2,515,000 | -23% | Arsani William | 14 Nov 2025 |
As of 31 Dec 2025, 116 institutional investors reported holding 38,119,020 shares of Design Therapeutics, Inc. - Common Stock, $0.0001 par value per share (DSGN). This represents 62% of the company’s total 61,756,000 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Design Therapeutics, Inc. - Common Stock, $0.0001 par value per share (DSGN) together control 55% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| SR One Capital Management, LP | 11% | 6,526,476 | 0% | 8.7% | $61,218,345 |
| Point72 Asset Management, L.P. | 8.7% | 5,372,004 | +61% | 0.08% | $50,389,398 |
| Logos Global Management LP | 4% | 2,500,000 | -32% | 1.6% | $23,450,000 |
| BAKER BROS. ADVISORS LP | 3.6% | 2,233,099 | +30% | 0.12% | $20,946,469 |
| BlackRock, Inc. | 3.4% | 2,117,156 | +3.6% | 0% | $19,858,924 |
| VANGUARD GROUP INC | 2.6% | 1,630,910 | +13% | 0% | $15,297,936 |
| Vivo Capital, LLC | 2.6% | 1,612,903 | 0.98% | $15,129,030 | |
| Almitas Capital LLC | 2.5% | 1,530,435 | 0% | 3.2% | $14,355,480 |
| RA CAPITAL MANAGEMENT, L.P. | 2.4% | 1,461,381 | +207% | 0.14% | $13,707,754 |
| Driehaus Capital Management LLC | 1.9% | 1,179,817 | +9.6% | 0.08% | $11,066,683 |
| Woodline Partners LP | 1.5% | 944,039 | +54% | 0.03% | $8,855,086 |
| Kynam Capital Management, LP | 1.3% | 784,606 | -24% | 0.48% | $7,359,604 |
| FMR LLC | 1.2% | 771,268 | +4.1% | 0% | $7,234,494 |
| MORGAN STANLEY | 1.1% | 702,306 | +299% | 0% | $6,587,630 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.1% | 679,590 | -2.3% | 0% | $6,375,975 |
| STATE STREET CORP | 1% | 647,636 | +2.1% | 0% | $6,074,826 |
| ACADIAN ASSET MANAGEMENT LLC | 0.99% | 612,768 | -0.76% | 0.01% | $5,742,000 |
| Frazier Life Sciences Management, L.P. | 0.84% | 521,000 | -73% | 0.13% | $4,886,980 |
| CITADEL ADVISORS LLC | 0.74% | 459,874 | -17% | 0% | $4,313,618 |
| D. E. Shaw & Co., Inc. | 0.71% | 438,894 | +18% | 0% | $4,116,825 |
| Invesco Ltd. | 0.5% | 305,757 | +1996% | 0% | $2,868,000 |
| DIMENSIONAL FUND ADVISORS LP | 0.48% | 297,921 | +6.5% | 0% | $2,795,478 |
| RENAISSANCE TECHNOLOGIES LLC | 0.46% | 287,100 | +4.7% | 0% | $2,692,998 |
| NORTHERN TRUST CORP | 0.46% | 286,572 | -3.4% | 0% | $2,688,045 |
| GOLDMAN SACHS GROUP INC | 0.44% | 270,654 | +3.5% | 0% | $2,538,735 |
Institutional Holders of Design Therapeutics, Inc. - Common Stock, $0.0001 par value per share (DSGN) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 6,458,765 | $68,711,725 | +$2,029,979 | $10.64 | 54 |
| 2025 Q4 | 38,119,020 | $357,552,417 | +$35,421,791 | $9.38 | 116 |
| 2025 Q3 | 34,492,564 | $259,728,206 | +$644,093 | $7.53 | 94 |
| 2025 Q2 | 34,530,294 | $116,365,282 | +$265,374 | $3.37 | 91 |
| 2025 Q1 | 34,459,430 | $133,014,167 | +$2,133,109 | $3.86 | 95 |
| 2024 Q4 | 33,460,789 | $206,451,772 | +$9,368,489 | $6.17 | 94 |
| 2024 Q3 | 32,032,058 | $172,330,017 | +$1,330,349 | $5.38 | 98 |
| 2024 Q2 | 32,097,220 | $107,523,187 | +$4,413,890 | $3.35 | 92 |
| 2024 Q1 | 30,700,544 | $123,722,605 | -$3,107,582 | $4.03 | 88 |
| 2023 Q4 | 31,717,256 | $84,046,693 | -$1,847,569 | $2.65 | 87 |
| 2023 Q3 | 32,867,255 | $77,567,491 | -$67,849,061 | $2.36 | 84 |
| 2023 Q2 | 38,786,588 | $244,358,163 | +$738,881 | $6.30 | 96 |
| 2023 Q1 | 38,691,853 | $223,252,292 | -$16,074,747 | $5.77 | 94 |
| 2022 Q4 | 40,381,322 | $414,296,202 | -$600,847 | $10.26 | 81 |
| 2022 Q3 | 39,933,593 | $667,698,632 | +$24,544,231 | $16.72 | 76 |
| 2022 Q2 | 38,690,076 | $541,665,132 | +$9,157,438 | $14.00 | 70 |
| 2022 Q1 | 37,990,461 | $613,724,140 | +$27,782,038 | $16.15 | 62 |
| 2021 Q4 | 36,170,094 | $773,127,906 | +$50,180,616 | $21.41 | 58 |
| 2021 Q3 | 28,281,317 | $414,830,000 | +$5,824,856 | $14.69 | 52 |
| 2021 Q2 | 27,817,792 | $545,865,000 | +$37,059,194 | $19.89 | 49 |
| 2021 Q1 | 25,762,953 | $755,185,000 | +$755,158,004 | $29.90 | 43 |